Lifestyle Asset Management Inc. Has $1.23 Million Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Lifestyle Asset Management Inc. boosted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 7.0% during the third quarter, Holdings Channel.com reports. The fund owned 3,697 shares of the company’s stock after acquiring an additional 241 shares during the period. Medpace comprises 0.7% of Lifestyle Asset Management Inc.’s investment portfolio, making the stock its 28th largest position. Lifestyle Asset Management Inc.’s holdings in Medpace were worth $1,234,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Private Advisor Group LLC raised its stake in Medpace by 10.1% in the first quarter. Private Advisor Group LLC now owns 1,065 shares of the company’s stock valued at $430,000 after purchasing an additional 98 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Medpace during the 1st quarter worth approximately $5,179,000. Janney Montgomery Scott LLC boosted its position in shares of Medpace by 7.5% during the 1st quarter. Janney Montgomery Scott LLC now owns 7,630 shares of the company’s stock worth $3,084,000 after acquiring an additional 532 shares in the last quarter. Daiwa Securities Group Inc. boosted its position in shares of Medpace by 391.6% during the 1st quarter. Daiwa Securities Group Inc. now owns 1,696 shares of the company’s stock worth $686,000 after acquiring an additional 1,351 shares in the last quarter. Finally, Texas Permanent School Fund Corp increased its stake in Medpace by 1.3% in the first quarter. Texas Permanent School Fund Corp now owns 20,409 shares of the company’s stock valued at $8,248,000 after acquiring an additional 264 shares during the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Trading Down 1.4 %

MEDP stock opened at $353.42 on Friday. Medpace Holdings, Inc. has a 1-year low of $268.80 and a 1-year high of $459.77. The stock has a 50-day moving average price of $341.44 and a 200-day moving average price of $377.59. The firm has a market cap of $10.98 billion, a PE ratio of 30.95, a price-to-earnings-growth ratio of 1.76 and a beta of 1.37.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, October 21st. The company reported $3.01 EPS for the quarter, topping the consensus estimate of $2.77 by $0.24. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The company had revenue of $533.32 million during the quarter, compared to the consensus estimate of $540.99 million. During the same quarter last year, the firm posted $2.22 EPS. The company’s quarterly revenue was up 8.3% on a year-over-year basis. On average, analysts forecast that Medpace Holdings, Inc. will post 11.93 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on MEDP shares. Baird R W downgraded Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Jefferies Financial Group lowered Medpace from a “buy” rating to a “hold” rating and reduced their price objective for the company from $415.00 to $345.00 in a research note on Wednesday, September 25th. Guggenheim decreased their target price on Medpace from $464.00 to $432.00 and set a “buy” rating on the stock in a research report on Wednesday, July 24th. StockNews.com cut shares of Medpace from a “buy” rating to a “hold” rating in a report on Friday, September 27th. Finally, Robert W. Baird cut shares of Medpace from an “outperform” rating to a “neutral” rating and lowered their price objective for the stock from $413.00 to $349.00 in a research report on Wednesday, October 23rd. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Medpace presently has a consensus rating of “Hold” and an average target price of $380.00.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.